Stock Titan Trading tools for traders and investors.

-

10:40:12 AM

Last BNTX Stock Market News

BNTX - BioNTech SE

12/10/20 10:46 AM

Nasdaq : BNTX

Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine

Data from 43,448 participants, half of whom received BNT162b2 and half of whom received placebo, showed that the vaccine candidate was well tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection 7 days or more after the second dose Vaccine efficacy observed

RHEA-AI

neutral

12/09/20 11:03 AM

Nasdaq : BNTX

Pfizer and BioNTech Achieve Health Canada Authorization for Their Vaccine to Combat COVID-19

Health Canada authorizes supply of COVID-19 mRNA vaccine under Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 The companies will supply a minimum of 20 million doses to Canada through 2021 KIRKLAND, QUEBEC, CANADA and MAINZ, GERMANY, December

RHEA-AI

very positive

12/02/20 3:32 AM

Nasdaq : BNTX

BioNTech to Hold Press Conference to Provide an Update on COVID-19 Vaccine Development Program

Mainz, Germany, December 02, 2020 - BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") will hold a press conference including a video webcast on Wednesday, December 2, 2020, to provide an update on the status of the COVID-19 vaccine development program of its lead vaccine

RHEA-AI

neutral

12/02/20 2:05 AM

Nasdaq : BNTX

Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19

U.K. regulator, MHRA, authorizes supply of COVID-19 mRNA vaccine for emergency supply under Regulation 174; Companies are ready to deliver the first doses to the U.K. immediately First authorization for a COVID-19 vaccine represents a breakthrough scientific achievement to help combat this

RHEA-AI

positive

12/01/20 5:00 AM

Nasdaq : BNTX

Pfizer and BioNTech Submitted Application for Conditional Marketing Authorization for COVID-19 Vaccine to the EMA

EMA confirms successful application for Conditional Marketing Authorization for BNT162b2, which Pfizer and BioNTech submitted yesterday In addition to submission to EMA, FDA and U.K. MHRA, the companies have also initiated additional rolling submissions across the globe including in Australia,

RHEA-AI

neutral

11/25/20 7:45 AM

Nasdaq : BNTX

BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel Immunotherapies

Long-term collaboration underpins BioNTech's strategy to leverage Artificial Intelligence (AI) and Machine Learning (ML) technologies to support the discovery and development of novel immunotherapies based on InstaDeep's DeepChain TM technology platform BioNTech and InstaDeep to establish a joint

RHEA-AI

very positive

11/20/20 6:45 AM

Nasdaq : BNTX

Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine

In addition to today's submission to the FDA, the companies have already initiated rolling submissions across the globe including in Australia, Canada, Europe, Japan and the U.K., and plan to submit applications immediately to other regulatory agencies around the world Based on current projections,

RHEA-AI

neutral

11/18/20 7:13 AM

Nasdaq : BNTX

Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints

Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose; 170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group Efficacy was consistent across age, gender, race and

RHEA-AI

neutral

11/11/20 6:15 AM

Nasdaq : BNTX

Pfizer and BioNTech Reach an Agreement to Supply the EU with 200 Million Doses of Their BNT162b2 mRNA-based Vaccine Candidate against COVID-19

Agreement provides a supply of 200 million doses and an option to request additional 100 million doses, with deliveries starting by the end of 2020, subject to regulatory approval The vaccine supply for the EU will be produced by BioNTech's manufacturing sites in Germany and Pfizer's manufacturing

RHEA-AI

neutral

11/10/20 7:15 AM

Nasdaq : BNTX

BioNTech Announces Third Quarter 2020 Financial Results and Corporate Progress

BNT162b2 vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in first interim efficacy analysis from Phase 3 trial Analysis evaluated 94 confirmed cases of COVID-19 in trial participants Study enrolled

RHEA-AI

neutral

Prev 1 2 3 4 5 6 7 8 Next